ARN-75039 low dose

Small molecule

IIrrua Specialist Teaching Hospital

ARN-75039 low dose is one of 5 small molecule programs targeting Lassa fever. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lassa FeverActive, not recruiting

Lassa FeverPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Lassa Fever

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

4 3

Avigan

AAppili Therapeutics Inc.

Phase 2

2 4

ARN-75039

AArisan Therapeutics, Inc.

Phase 2

1 5

ARN-75039 low dose

IIrrua Specialist Teaching Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2/3Recruiting

Lassa Fever

NCT06212336

Clinical

Trials by Indication[1]

Lassa fever1 trial

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Recruiting·IIrrua Specialist Teaching Hospital·Phase 2/3·NCT06212336·1,755 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARN-75039 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARN-75039 low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARN-75039 low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Irrua Specialist Teaching Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IIrrua Specialist Teaching Hospital

ARN-75039 low dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Lassa fever1 trial

References

Drug Info

Quick Facts

Related News